US · Healthcare · Drug Manufacturers - General
EPS came in at 0.01 against a street estimate of -0.28 — a beat of 103.6%.
Analysts rate Amarin Corporation PLC a sell (0 buy, 0 hold, 2 sell out of 2) with an average price target of $13.00.
MIXED Amarin delivered its first profitable quarter in two years, but revenue fell 20.4% as U.S. pricing pressure offset stable volumes. International demand grew strongly, while 2027 pricing and EMT2’s commercial path remain uncertain. Q3 FY26 European in-market demand increased an estimated 68%, Rest of World demand rose 46%, and U.S. branded volume was relatively flat despite revenue pressure. Analysts focused on the disconnect between stable U.S. volume and falling revenue, future pricing, European reimbursement, and additional IPE applications. Management attributed U.S. weakness to pricing, highlighted Recordati’s expansion, and said EMT2 requires further evaluation. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| Sarissa Capital Management LP | 7.92% |
| Acadian Asset Management LLC | 3.41% |
| Kynam Capital Management, LP | 2.52% |
| Morgan Stanley - Brokerage Accounts | 1.06% |
| Waterfront Wealth Inc. | 1.01% |
| Brooklands Fund Management Limited | 0.84% |
| Eversept Partners, LP | 0.69% |
| Millennium Management LLC | 0.55% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Amarin Corporation PLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.